sterically congested framework requires highly active catalytic
species, (2) precise discrimination between primary alkyl and
secondary alkyl groups is crucial to achieve high enantioselec-
tivity, (3) and the obtained chiral alcohols are key intermediates
for the synthesis of biologically active compounds, including
solifenacin, an M3 receptor antagonist.6 We expected that the
BINAP/chiral 1,4-diamine-Ru catalysts would be appropriate
for this hydrogenation because the medium-sized diamine-Ru
chelate structure has enough space for an approach of the
bicyclic ketones to the reaction site. The chiral environment of
the Ru catalyst constructed from chiral diphosphine and diamine
ligands can be tuned by changing the combination.
Scheme 1
We recently reported asymmetric hydrogenation of 3-qui-
nuclidinone (1a) catalyzed by an (S,S)-XylSkewphos/R-
picolylamine-Ru complex.7 The high catalytic activity achieved
complete conversion in the reaction with a substrate-to-catalyst
molar ratio (S/C) of 100 000 (15 atm H2, 30-40 °C, 4 h) to
give (R)-3-quinuclidinol [(R)-2a] in 88% ee. A patent described
that 97% ee of 2a was obtained in the reaction by using the
(R)-DM-SEGPHOS/(S)-DM-DAIPEN-Ru catalyst, but the
reactivity was insufficient for practical use (S/C ) 1000, 30
atm of H2, rt, 16 h, 97.5% conversion).8 Therefore, we aimed
to develop a Ru catalyst with both high activity and enantiose-
lectivity for the hydrogenation of bicyclic ketones.
We selected 1a as a typical substrate for optimization of
the catalyst structure due to the synthetic importance of
product 2a (Table 1).6 When 1a (1.63 g, 13 mmol) was
hydrogenated with RuCl2[(R)-binap][(S)-ipban] [(R,S)-3a]3
(S/C ) 10 000) in t-C4H9OK containing 2-propanol under
20 atm of H2, (S)-3-quinuclidinol [(S)-2a] was obtained in
92% ee quantitatively (entry 1). The reaction with the
diastereomeric (S,S)-3a gave (R)-2a in 88% ee (entry 2). The
enantioselection was primarily dependent on the configura-
tion of BINAP, and the (R)-BINAP/(S)-diamine combination
was preferable to the R/R diastereomer. The use of (S)-
BINAP/(R)-IPHAN-Ru complex (S,R)-3b3 resulted in an
excellent ee of 97% (entry 3). Introduction of two methyl
groups at the R-carbons of the amino groups with an R
configuration appeared to fix the diamine-Ru chelate ring
appropriately. The high catalytic activity of the (S,R)-3b-t-
C4H9OK system achieved complete conversion in the reaction
with an S/C of 50 000 under 50 atm of H2 without
loss of enantioselectivity (entry 4). The (S)-TolBINAP/(R)-
IPHAN-Ru complex [(S,R)-3c] exhibited catalyst efficiency
comparable to that of (S,R)-3b (entry 5). The acetonide
moiety of the 1,4-diamine was also important for attaining
high catalyst performance. Thus, the ee value of 2a in the
reaction with the (S)-BINAP/(2R,5R)-2,5-hexanediamine-Ru
complex [(S,R)-3d] decreased to 95%, and high pressure
conditions (80 atm) were required for completion of the
hydrogenation with an S/C of 20 000 (entries 6 and 7). High
enantioselectivity was gained by using a combination of
Table 1. Asymmetric Hydrogenation of Ketones with
Bicyclo[2.2.2] Skeletons 1a
entry ketone 1 Ru cat. 3 S/Cb H2 (atm) time (h) % ee of 2c
1
1a
1a
1a
1a
1a
1a
1a
1a
1b
(R,S)-3a 10000
(S,S)-3a 10000
(S,R)-3b 10000
(S,R)-3b 50000
(S,R)-3c 50000
(S,R)-3d 10000
(S,R)-3d 20000
(R,S)-3e 10000
20
20
20
50
50
20
80
20
20
5
5
92 (S)
2
88 (R)
97 (R)d
97 (R)d
97 (R)d
95 (R)
95 (R)d
97 (S)
3
5
4e
5e
6
24
24
5
16
5
2
7f
8
9g
(S,R)-3b
1000
98 (S)h
a Unless otherwise stated, reactions were conducted at 25 °C using 13
mmol of 1 in 2-propanol (2.7 mL) containing 3 and t-C4H9OK (20 mM).
Complete conversion was observed in all cases. b Substrate/catalyst molar
ratio. c Determined by chiral HPLC analysis after conversion to the benzoate.
d The isolated yield was 99%. e 1a (18.8 g, 150 mmol) and 2-propanol (49
mL) were used. f 1a (3.3 g, 26 mmol) and 2-propanol (8.4 mL) were used.
g 1b (168 mg, 1.35 mmol) and a 3:1 2-propanol-t-C4H9OH (6.4 mL)
mixture were used. h The isolated yield was 90%.
(6) Naito, R.; Yonetoku, Y.; Okamoto, Y.; Toyoshima, A.; Ikeda, K.;
Takeuchi, M. J. Med. Chem. 2005, 48, 6597–6606.
(7) Tsutsumi, K.; Katayama, T.; Utsumi, N.; Murata, K.; Arai, N.;
Kurono, N.; Ohkuma, T. Org. Process Res. DeV. 2009, 13, 625–628.
(8) Takenaka, M. Chem. Abstr. 2005, 143, 422509; Jpn. Kokai Tokkyo
Koho 2005306804 A 20051104, 2005.
Org. Lett., Vol. 12, No. 15, 2010
3381